Renascience Inc.
4889.TJPXHealthcareMedical - Pharmaceuticals
Latest quote
¥1,330
+¥28.00 · +2.15%
4889.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteRenascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Toshio Miyata
- Listed since
- Sep 24, 2021
- Employees
- 3
Market position
Day range
Current ¥1,330
52-week range
Current ¥1,330
- Open
- ¥1,299
- Previous close
- ¥1,302
- Volume
- 445.2K
- 0.84× average
- Average volume
- 528.04K
- Average daily volume
- Market cap
- 18.32B JPY
- Beta
- 1.7
- Market reference 1
- 50-day average
- ¥1,488.74
- -10.66% below average
- 200-day average
- ¥1,596.51
- -16.69% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 18.21B JPY
- P/E (TTM)
- -55.23×
- P/B (TTM)
- 5.65×
- P/S (TTM)
- 267.28×
- EV / EBITDA
- -51.02×
- Earnings yield
- -1.39%
- Free cash flow yield
- -1.35%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 93.66%
- Operating margin
- -491.15%
- Net margin
- -461.59%
- Return on equity
- -9.07%
- Return on assets
- -8.60%
- Return on invested capital
- -10.74%
Financial health
- Debt / equity
- 0×
- Current ratio
- 19.4×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 68.55M JPY | 132.69M JPY | 194.17M JPY | 100.55M JPY | 139.33M JPY |
| Cost of goods sold | 4.35M JPY | 3.75M JPY | 28.52M JPY | 250K JPY | 61.74M JPY |
| Gross profit | 64.21M JPY | 128.95M JPY | 165.64M JPY | 100.3M JPY | 77.6M JPY |
| Research and development | — | 132.87M JPY | 236M JPY | 235M JPY | 82.71M JPY |
| Selling, general, and administrative | 421.09M JPY | 307.77M JPY | 167M JPY | 185M JPY | 193M JPY |
| Operating expenses | 421.09M JPY | 307.77M JPY | 417.98M JPY | 434.17M JPY | 290M JPY |
| Interest income | 3.53M JPY | 924K JPY | 24K JPY | 26K JPY | 20K JPY |
| Interest expense | — | — | — | — | 5.37M JPY |
| Depreciation and amortization | — | 62K JPY | 1.84M JPY | 1.38M JPY | 3.07M JPY |
| Operating income | −356.89M JPY | −178.83M JPY | −252.34M JPY | −333.87M JPY | −210.84M JPY |
| Net income | −301.28M JPY | 113.43M JPY | −258.34M JPY | −335.8M JPY | −254.29M JPY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -5.95
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
4889.T peers
Continue in GoAI
Research 4889.Tresearch.disclaimer